Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

June 27, 2018

Primary Completion Date

February 18, 2025

Study Completion Date

July 1, 2026

Conditions
Metastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Neoplasm in the BrainStage IV Lung Cancer AJCC v8
Interventions
BIOLOGICAL

Bevacizumab

Given IV

PROCEDURE

Biopsy Procedure

Undergo tumor biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

DRUG

Osimertinib

Given PO

Trial Locations (18)

10032

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

33607

Moffitt Cancer Center-International Plaza, Tampa

33612

Moffitt Cancer Center, Tampa

43210

Ohio State University Comprehensive Cancer Center, Columbus

66205

University of Kansas Clinical Research Center, Fairway

University of Kansas Hospital-Westwood Cancer Center, Westwood

68118

Nebraska Medicine-Village Pointe, Omaha

68123

Nebraska Medicine-Bellevue, Bellevue

68198

University of Nebraska Medical Center, Omaha

73104

University of Oklahoma Health Sciences Center, Oklahoma City

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

90033

Los Angeles General Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

91105

Keck Medical Center of USC Pasadena, Pasadena

95817

University of California Davis Comprehensive Cancer Center, Sacramento

06510

Smilow Cancer Center/Yale-New Haven Hospital, New Haven

06520

Yale University, New Haven

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH